C4 earnings beat by $0.09, revenue topped estimates
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
C4 Therapeutics Inc (CCCC)
C4 Therapeutics Inc stock price live, this page displays NASDAQ CCCC stock exchange data. View the CCCC premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the C4 Therapeutics Inc real time stock price chart below.
What Is the C4 Therapeutics Inc Stock Price Today?
The C4 Therapeutics Inc stock price today is 2.29.
What Is the Stock Symbol for C4 Therapeutics Inc?
The stock symbol for C4 Therapeutics Inc is ""CCCC.""
What Stock Exchange Does C4 Therapeutics Inc Trade On?
C4 Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is C4 Therapeutics Inc a Good Stock to Buy?
Determining whether C4 Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CCCC quote. (ISIN: US12529R1077)
What Is the C4 Therapeutics Inc Stock Price Today?
The C4 Therapeutics Inc stock price today is 2.29.
What Is the Stock Symbol for C4 Therapeutics Inc?
The stock symbol for C4 Therapeutics Inc is ""CCCC.""
What Stock Exchange Does C4 Therapeutics Inc Trade On?
C4 Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is C4 Therapeutics Inc a Good Stock to Buy?
Determining whether C4 Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CCCC quote. (ISIN: US12529R1077)
NASDAQ
Currency in USD
2.29
-0.13(-5.37%)
Closed·
After Hours
2.31+0.02(+0.87%)
·
Fair Value
An estimate of a C4's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.23
2.43
52 wk Range
1.09
7.36
CCCC Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 12 days
More Info
Fair Value
An estimate of a C4's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.232.43
52 wk Range
1.097.36
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CCCC Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a C4's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
15.80
Upside
+589.96%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- C4 Therapeutics stock hits 52-week low at $2.21
- Investing.com
- C4 Therapeutics Announces Board Member Retirement
- Investing.com
- C4 earnings beat by $0.09, revenue topped estimates
- Investing.com
- C4 Therapeutics Announces Board Member Retirement
- Investing.com
- C4 Therapeutics stock hits 52-week low at $1.38
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
C4 Therapeutics Inc Company Profile
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
C4 Therapeutics Inc SWOT Analysis
Promising Pipeline | Explore C4 Therapeutics' lead candidate CFT1946, a BRAF V600X degrader showing superior efficacy in preclinical studies and early clinical trials |
Clinical Progress | Delve into early clinical data revealing encouraging anti-tumor activity and favorable safety profile of CFT1946 compared to historical benchmarks |
Market Potential | Learn how CFT1946's unique mechanism and safety profile could position it as a preferred treatment across various BRAF V600 mutant-driven cancers |
Analyst Outlook | BMO Capital Markets rates C4 Therapeutics as Outperform with a $20 price target, suggesting significant upside potential from current levels |
Compare CCCC to Peers and Sector
Metrics to compare | CCCC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCCCCPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.6x | −2.0x | −0.5x | |
PEG Ratio | −0.05 | −0.11 | 0.00 | |
Price/Book | 0.8x | 0.9x | 2.6x | |
Price / LTM Sales | 4.1x | 23.3x | 3.2x | |
Upside (Analyst Target) | 189.3% | 153.2% | 40.5% | |
Fair Value Upside | Unlock | 16.6% | 4.4% | Unlock |
Analyst Ratings
4 Buy
2 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 15.80
(+589.96% Upside)
Earnings
Latest Release
May 07, 2025
EPS / Forecast
-0.37 / -0.46
Revenue / Forecast
7.24M / 4.74M
People Also Watch
FAQ
What Stock Exchange Does C4 Trade On?
C4 is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for C4?
The stock symbol for C4 is "CCCC."
What Is the C4 Market Cap?
As of today, C4 market cap is 163.32M.
What Is C4's Earnings Per Share (TTM)?
The C4 EPS (TTM) is -1.48.
When Is the Next C4 Earnings Date?
C4 will release its next earnings report on 05 Aug 2025.
From a Technical Analysis Perspective, Is CCCC a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has C4 Stock Split?
C4 has split 0 times.
How Many Employees Does C4 Have?
C4 has 110 employees.
What is the current trading status of C4 (CCCC)?
As of 25 Jul 2025, C4 (CCCC) is trading at a price of 2.29, with a previous close of 2.42. The stock has fluctuated within a day range of 2.23 to 2.43, while its 52-week range spans from 1.09 to 7.36.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.